Evoke Pharma Inc. (EVOK)

[cash_cow1]

Evoke Pharma inc and the shareholders is the owners of a $4 billion dollar annual prescription drug market, with only one oral pill on the market that doesn't work very well to treat Gastroparesis disease, because like food and oral medication it is delay in the stomach because of gastric delay emptying of the stomach contents.

Gimoti nasal spray by pass the GI system and goes straight to the bloodstream which start to relief symptoms cause by Gastroparesis in minutes. Unlike the Pill form which takes hours and some times a day to work to relief symptoms, because of gastric delay empty of the stomach.

Evoke is expected to take a huge portion of the prescription market to treat Gastroparesis and Diabetic Gastroparesis disease in females. The company expect first year of sales up to 2/3 to treat the Diabetic Gastroparesis disease up to a $4 billion prescription market. Gimoti nasal spray the first of it kind to treat adult Females Diabetic Gastroparesis disease. Evoke expect millions of female worldwide to benefit from the use of Gimoti to treat their symptoms cause by diabetic gastroparesis disease.